Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)

This study was to evaluate the safety and tolerability of bintrafusp alfa in combination with other anti-cancer therapies in participants with locally advanced or advanced cervical cancer.


Eligibility Criteria:
Inclusion Criteria:

* Inclusion Criteria for participants enrolling into Cohort 1:
* Study participants had documented persistent, recurrent, or metastatic squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix
* Study participants had not been treated with systemic chemotherapy and were not amenable to curative treatment
* Prior radiation with or without radio-sensitizing chemotherapy was allowed
* Inclusion Criteria for participants enrolling into Cohort 2:
* Participants had documented evidence of cervical adenocarcinoma, squamous cell carcinoma, or adenosquamous carcinoma International Federation of Gynecology and Obstetrics (FIGO) 2018 Stages 1B2 to 4A
* Participants had not received prior chemotherapy or radiotherapy for cervical cancer
* Inclusion Criteria for all participants:
* Archival tumor tissue sample or newly obtained core or excisional biopsy was required
* Participants who had Eastern Cooperative Oncology Group (ECOG) Performance status (PS) of 0 to 1 were eligible
* Participants had a life expectancy greater than or equal to 12 weeks
* Participants had adequate hematological, hepatic, renal, and coagulation function as defined in the protocol
* Participants with known Human immunodeficiency virus (HIV) infections were eligible if the criteria described in the protocol were met
* Participants with Hepatitis B virus (HBV) and/or Hepatitis C virus (HCV) infections were eligible if the criteria described in the protocol were met
* Other protocol defined inclusion criteria could apply

Exclusion Criteria:

* Exclusion Criteria for All Participants were:
* Participants with active central nervous system (CNS) metastases causing clinical symptoms or metastases that required therapeutic intervention were excluded. Participants with a history of treated CNS metastases (by surgery or radiation therapy) were not eligible unless they had fully recovered from treatment, demonstrated no progression for at least 4 weeks, and were not using steroids for at least 7 days prior to the start of study intervention
* Participants that received any organ transplantation, including allogeneic stem-cell transplantation, but with the exception of transplants that did not require immuno-suppression
* Participants with significant acute or chronic infections
* Participants with active autoimmune disease that might have deteriorated when receiving an immuno-stimulatory agent
* Participants with clinically significant cardiovascular/cerebrovascular disease including: a cerebral vascular accident/stroke, myocardial infarction, unstable angina, congestive heart failure, or serious cardiac arrhythmia
* Participants with a history of bleeding diathesis or recent major bleeding events
* Participant that had received prior cancer treatment with any other immunotherapy or checkpoint inhibitors or any other immune-modulating monoclonal antibody (mAb)
* Exclusion Criteria for Participants in Cohort 1A related to use of bevacizumab were:
* Participants with inadequately controlled hypertension
* Prior history of hypertensive crisis or hypertensive encephalopathy
* Participants with significant vascular disease within 6 months prior to Screening
* Participants with a history of hemoptysis within 1 month prior to Screening
* Current use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes
* Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to the first dose of bevacizumab
* Participants with a history of abdominal or trache-oesophageal fistula or gastrointestinal (GI) perforation within 6 months prior to Screening
* Participants with clinical signs of GI obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding
* Participants with evidence of abdominal free air not explained by paracentesis or recent surgical procedure
* Participants with serious, non-healing wound, active ulcer, or untreated bone fracture
* Participants with proteinuria
* Other protocol defined exclusion criteria could apply